Unaudited Financial results of the Company for the quarter ended September 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and 0.8 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Prevest Denpro posted steady Q2 FY26 results with standalone revenue from operations of Rs 1,866.30 lakhs, up about 15% from Rs 1,625.67 lakhs in Q2 FY25. Net profit for the quarter rose to Rs 556.95 lakhs from Rs 483.85 lakhs, while EPS stood at Rs 4.64 versus Rs 4.03. For H1 FY26, revenue grew around 16% to Rs 3,438.57 lakhs and net profit climbed about 20% to Rs 1,020.38 lakhs. Consolidated figures were largely in line with standalone, with subsidiaries Denvisio Biomed and Axiodent Inc. (USA) contributing marginally. The statutory auditor issued an unmodified limited review report with no qualifications or concerns.
Positive for shareholders — consistent double-digit revenue and profit growth on a year-on-year basis with a clean audit report, suggesting stable business momentum, though growth rates are not exceptional enough to drive a sharp re-rating on their own.